Ketamine’s Regulatory Vacuum Is Now an Enforcement Story

The clearest dividing line in U.S. ketamine therapy is one most patients don’t know exists: Spravato (esketamine) is FDA-approved and subject to a Risk Evaluation and Mitigation Strategy (REMS) that requires in-clinic administration and at least two hours of observed monitoring. Off-label IV, IM, oral, and at-home ketamine — the much larger market — is subject to no comparable federal framework. (Journal of Medical Regulation)

That gap has gotten more visible in 2026. The trade press is now describing the off-label ketamine landscape less as a regulatory question and more as an enforcement story — state medical boards, federal regulators, and increasingly the courts shaping practice through audits and disciplinary actions rather than prospective rules. Texas is the most-watched current example: the state medical board is considering tighter rules on supervision, dosing, and patient screening as off-label ketamine usage continues to expand for PTSD, depression, and substance-use indications.

Two federal timelines are pressing on this. The DEA and HHS extended telemedicine flexibilities for controlled-substance prescribing — which applied to many at-home compounded ketamine business models — through December 31, 2026. A permanent rule is still in process. If the flex isn’t extended or replaced, the at-home ketamine market faces a structural disruption at the end of the year. Separately, the Texas attorney general’s office and several state medical boards have begun investigations of at-home ketamine providers tied to specific adverse events.

For patients trying to evaluate a ketamine therapy provider in Arizona right now: the relevant questions are whether the provider is Spravato-REMS certified (a documentable status), whether off-label administration is supervised in-clinic vs. at-home, whether vital-signs monitoring is performed, and whether the prescriber has an established relationship with a mental-health clinician for indications like treatment-resistant depression or PTSD. None of these are required by federal rule for off-label ketamine. All of them appear in the enforcement record of providers who have run into trouble. (Psychiatry Advisor)

This is the kind of regulatory landscape where most of the rule-making, in practice, ends up being done by the courts.